Table 1.
Monoclonal antibodies against CHIKV.
| ORIGIN | NAME | TARGET | EFFECT | DOSAGE | REFERENCES |
|---|---|---|---|---|---|
| Human | 5F10; 8B10 | E2 (5F10), E2 | Prophylactic: 100% protection | 250μg | Warter et al. 2011101 |
| and/or E1 (8B10) | Therapeutic: Delay in lethality but did not fully protect | Fric et al. 2013103 | |||
| C9 | E2 | Prophylactic: 100% protection | 100μg | Selvarajah et al. 2013106 | |
| |
|
|
Therapeutic: 100% protection |
|
|
| Mouse | CHK-102; CHK-152; CHK-166; CHK-263 | E1 and E2 | Prophylactic: 100% protection in immunocompromised mice | 100μg | Pal et al. 201350 |
| Therapeutic: Mouse model: 58% (CHK-152) & 63% (CHK-166) protection from death | |||||
| Rhesus macaques: Significant reduction of viral load and spread (combination of CHK-152&CHK-166) | 15mg/kg | Pal et al. 2014172 | |||
| 1.3A2; 4.6F5 | E2 | Prophylactic: 100% protection against CHIKV arthritis, significant suppression of viremia | 400μg | Goh et al. 2013105 | |
| CK47 | E1 | In vitro: Inhibits virus release from infected cells | Masrinoul et al. 2014104 | ||
| 1.7B2; 4.1H11; 4.8E2; 4.10A11; 5.1B12; 5.2F8, 5.2H7; 5.4G8; 5.5A11; 5.5D11; 5.5G9 | Capsid Protein | In vitro: Reactivity was demonstrated in ELISA, western blot and IFA | Goh et al. 2015107 |